Grant: Project Grant
York University (Toronto, Ontario)
$730,575.00
Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery
FY 2022-23
Summary
Mounting scientific evidence suggests that a unique population of leukemic stem cells (LSC) are responsible for driving acute myeloid leukemia growth and resistance to drug treatment. However extracting these LSC from patients and growing them under laboratory conditions in order to test and identify new drugs has proven difficult as without appropriate conditions they perish within 24-72h. This is because in the patient, LSC reside in a specialized 3D bone marrow environment which is lacking in petri dishes. This proposal aims to identify and tissue engineer the 3D bone marrow environment in petri dishes in order to keep LSC alive allowing for subsequent drug screening. Using this synthetic 3D bone marrow petri dish, off-patent drugs with predetermined targets will be tested on the LSC to identify novel molecular targets that can further be developed as anti-leukemia drugs.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
468535
Name
Sachlos Eleftherios
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery
Programtype2
Operating Grants
Orgnameinp2
York University (Toronto, Ontario)
Cihramount2
$730,575
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
3d Extracellular Matrix; Acute Myeloid Leukemia - Leukemic Stem Cells; Drug Discovery; Hematopoietic Stem Cells; In Vitro Myelosuppression Assay; Liquid Biopsy; Personalized Cancer Medicine; Screening; Stem Cell Niche; Tissue Engineering
Abstract
Mounting scientific evidence suggests that a unique population of leukemic stem cells (LSC) are responsible for driving acute myeloid leukemia growth and resistance to drug treatment. However extracting these LSC from patients and growing them under laboratory conditions in order to test and identify new drugs has proven difficult as without appropriate conditions they perish within 24-72h. This is because in the patient, LSC reside in a specialized 3D bone marrow environment which is lacking in petri dishes. This proposal aims to identify and tissue engineer the 3D bone marrow environment in petri dishes in order to keep LSC alive allowing for subsequent drug screening. Using this synthetic 3D bone marrow petri dish, off-patent drugs with predetermined targets will be tested on the LSC to identify novel molecular targets that can further be developed as anti-leukemia drugs.
Competitiondate
202209
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Sachlos, Eleftherios
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $730,575~ $0~
